PASSED: Eshoo Legislation to Establish ARPA-H and Boost Diversity in Clinical Trials

December 23, 2022
Press Release

WASHINGTON, D.C. – Today, Representative Anna G. Eshoo (CA-18) applauded passage of two major health bills she authored as part of the bipartisan Consolidated Appropriations Act, the ARPA-H Act and the DEPICT Act. The ARPA-H Act establishes the Advanced Research Projects Agency for Health, a new agency that will accelerate transformative breakthroughs to find cures and treat the world’s deadliest diseases. The DEPICT Act strengthens clinical trials by requiring drug and device manufacturers to submit a diversity action plan for enrolling trial participants that are reflective of the populations impacted by the disease.

“Today the future of biomedical research changed forever with the official establishment of ARPA-H by Congress. This groundbreaking health agency may now move forward with its mighty mission: curing and treating the world’s deadliest diseases, including cancer, diabetes, and Alzheimer’s,” said Eshoo. “Modeled after DARPA which paved the way for technology that built the world we live in today, like GPS and the internet, ARPA-H will lead to breakthroughs in health that many never imagined possible.”

“I’m also proud my DEPICT Act will become law. After years of non-binding recommendations from the FDA, the DEPICT Act will finally establish a statutory requirement for diversity in clinical trial participants. Diverse clinical trials are critical to ensuring that biomedical research is robust and equitable so that all Americans can be confident that treatments work for them, regardless of their backgrounds. We’re finally making good science the rule, not the recommendation,” said Eshoo.

The Consolidated Appropriations Act was passed by the Senate and will be signed into law by President Biden later this week.